Fable Therapeutics is a biopharmaceutical company developing protein-engineered biologics for obesity and metabolic disease. Its lead candidate, FBL-140, is an infrequently dosed monoclonal antibody antagonizing the activin receptor type II (ActR2) pathway to reduce body weight and fat while preserving lean muscle mass and improving… - View it on GitHub